Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for malaria patients with G6PD deficiency: safer drug regimens under study

NCT ID NCT07468513

First seen Mar 24, 2026 · Last updated May 21, 2026 · Updated 9 times

Summary

This study looks at how safe and effective primaquine is for treating vivax malaria in people with intermediate or deficient G6PD enzyme levels. About 100 adults will receive either a daily high dose for a week or a weekly dose, depending on their G6PD activity. The goal is to find a treatment that works without causing serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VIVAX MALARIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Arba Minch General Hospital

    NOT_YET_RECRUITING

    Arba Minch, Ethiopia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dr Marcus Lacerda

    RECRUITING

    Manaus, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dr Moses Laman and Dr Brioni Moore

    RECRUITING

    Alexishafen, Madang Province, Papua New Guinea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Papua New Guinea Institute of Medical Research

    RECRUITING

    Port Moresby, Magang, Papua New Guinea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.